RecruitingPhase 3NCT06247839
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Sponsor
Sharmin Ghaznavi
Enrollment
20 participants
Start Date
Sep 10, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Plain Language Summary
Simplified for easier understanding
This study explores how psilocybin (the active compound in certain mushrooms) affects the way people with depression think about themselves. Researchers believe that depression involves too much negative self-focused thinking, and psilocybin may help shift that pattern. Participants will receive psilocybin in a controlled, supervised clinical setting.
**You may be eligible if...**
- You are between 18 and 55 years old
- You have been diagnosed with moderate or greater major depressive disorder
- Your depression has lasted at least 3 months
- You score at least 18 on a standard depression scale
- You are able to give informed consent
**You may NOT be eligible if...**
- You have a personal or family history of psychosis, schizophrenia, or bipolar disorder
- You are currently taking certain psychiatric medications
- You have active suicidal intent
- You have a serious heart condition or other major medical illness
- You are pregnant or breastfeeding
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPsilocybin
COMP360 (Brand name of psilocybin to be used)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06247839
Related Trials
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401106 locations
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT0719650160 locations
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT0585068969 locations
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
NCT068207231 location
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT0711532932 locations